Trials / Conditions / Urinary Bladder Diseases

Urinary Bladder Diseases

22 registered clinical trials studyying Urinary Bladder Diseases — 3 currently recruiting.

Status	Trial	Sponsor	Phase
Completed	The COOKER-BLADDER Trial NCT05643963	Roland Seiler-Blarer	N/A
Recruiting	Stage II-IIIa Urothelial Cancer Randomizing Pre-operative Nivolumab With or Without Relatlimab NCT06237920	The Netherlands Cancer Institute	Phase 2
Active Not Recruiting	INTIBIA Pivotal Study NCT05250908	Coloplast A/S	N/A
Recruiting	Infectious Complications After Cystectomy: A Prospective Observational Study NCT05153694	Ludwig-Maximilians - University of Munich	—
Unknown	Safety and Efficacy Study of Tislelizumab in Combination With BCG in HR-NMIBC Patients (TACBIN-01) NCT04922047	RenJi Hospital	Phase 1 / Phase 2
Completed	Study Evaluating the Ability of a NIRS Module to Detect a Urodynamic Variation in Humans (DETTECH) NCT04161716	BioSerenity	N/A
Recruiting	Bladder Fiducial Markers and Multiparametric-MRI (Mp-MRI) to Optimize Bladder Chemo-radiotherapy NCT04442724	Cedars-Sinai Medical Center	N/A
Completed	Proliposomal Intravesical Paclitaxel for Treatment of Low-Grade, Stage Ta, Non Muscle Invasive Bladder Cancer NCT03081858	Lipac Oncology LLC	Phase 1 / Phase 2
Completed	Falls and Balance of Patients With Parkinson's Disease With Urinary Disturbance NCT03845725	Ordu University	—
Active Not Recruiting	Pediatric Urology Recovery After Surgery Endeavor (PURSUE) NCT03245242	Washington University School of Medicine	—
Completed	Eosinophilic Cystitis Mimicking Urothelial Neoplasia NCT04914442	Al-Azhar University	—
Completed	A Prospective, Observational, Multicenter Study of Patients Following Initiation of a New Course of Treatment NCT02386072	Astellas Scientific & Medical Affairs, Inc.	—
Completed	Safety of Pre-TURBT Intravesical Instillation of Escalating Doses of TC-3 Gel and MMC in NMIBC Patients NCT02307487	UroGen Pharma Ltd.	Phase 2
Completed	A Prospective Non-interventional Study in Overactive Bladder (OAB) Patients Prescribed Betmiga® as Part of Rou NCT02320773	Astellas Pharma Europe Ltd.	—
Completed	Bladder Management in Patients With Multiple Sclerosis: Optimizing Practice Patterns NCT01930799	Allergan	Phase 4
Completed	A Trial Comparing Combination Treatment (Solifenacin Plus Mirabegron) With One Treatment Alone (Solifenacin) NCT01908829	Astellas Pharma Europe Ltd.	Phase 3
Completed	Pilot Study to Evaluate the Clinical Response to Mitomycin-C in Hydrogel (TC-3) Administered Intravesically in NCT02891460	UroGen Pharma Ltd.	N/A
Completed	A Study to Evaluate the Efficacy and Safety of Mirabegron Compared to Solifenacin in Patients With Overactive NCT01638000	Astellas Pharma Europe Ltd.	Phase 3
Completed	A Study to Evaluate the Efficacy, Safety and Tolerability of Mirabegron and Solifenacin Succinate Alone and in NCT01340027	Astellas Pharma Europe B.V.	Phase 2
Terminated	A Study to Evaluate the Pain Relieving Effects, Safety, and Tolerability of JNJ-42160443 for the Relief of Bla NCT01060254	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Phase 2
Terminated	Hyperthermia Treatment in Conjunction With Mitomycin C Versus Bacillus Calmette-Guérin Immunotherapy (BCG) for NCT00384891	Medical Enterprises Europe B.V.	Phase 3
Withdrawn	SHTC - EUROPE-1 Synergo Hyperthermia-Chemotherapy by European Urologists' Research Operation Preserving Evolut NCT02254915	Medical Enterprises Europe B.V.	Phase 3